Compare HP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | TLX |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1994 | 2024 |
| Metric | HP | TLX |
|---|---|---|
| Price | $42.86 | $11.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $34.17 | $21.13 |
| AVG Volume (30 Days) | ★ 1.1M | 96.8K |
| Earning Date | 05-06-2026 | 08-19-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,746,013,000.00 | N/A |
| Revenue This Year | $9.50 | N/A |
| Revenue Next Year | $3.34 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | ★ 35.89 | N/A |
| 52 Week Low | $17.30 | $6.28 |
| 52 Week High | $41.90 | $12.60 |
| Indicator | HP | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 74.70 | 67.77 |
| Support Level | $32.42 | $10.01 |
| Resistance Level | N/A | $12.23 |
| Average True Range (ATR) | 1.58 | 0.21 |
| MACD | 0.99 | 0.19 |
| Stochastic Oscillator | 99.47 | 96.44 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.